Skip to main content

Table 3 Number and incidence rate of CVD, all-cause mortality and composite of CVD and all-cause mortality among urine albumin/creatinine ratio (UACR) groups (male) by multivariable Cox proportional hazard regression

From: Association of estimated glomerular filtration rate and urine albumin-to-creatinine ratio with incidence of cardiovascular diseases and mortality in chinese patients with type 2 diabetes mellitus – a population-based retrospective cohort study

 

UACR Group 1 (<0.5 mg/mmol)

(N = 5,821)

UACR Group 2

(0.5–0.9 mg/mmol)

(N = 8,796)

UACR Group 3

(1–1.4 mg/mmol)

(N = 3,846)

UACR Group 4

(1.5–1.9 mg/mmol)

(N = 2,183)

UACR Group 5

(2–2.4

mg/mmol)

(N = 1,474)

UACR Group 6

(2.5–3.4 mg/mmol)

(N = 1,906)

UACR Group 7

(3.5–4.9 mg/mmol)

(N = 1,563)

UACR Group 8

(5–9.9 mg/mmol)

(N = 2,308)

UACR Group 9

(10–24.9 mg/mmol)

(N = 1,765)

UACR Group 10

(25–34.9 mg/mmol)

(N = 406)

UACR Group 11 (≥35 mg/mmol)

(N = 1,021)

CVD

 Cumulative Cases with Event

242

417

245

167

112

159

123

248

206

50

154

 Cumulative Incidence Rate

4.2%

4.7%

6.4%

7.7%

7.6%

8.3%

7.9%

10.7%

11.7%

12.3%

15.1%

 Person-years

268,568

399,457

172,506

95,953

65,849

84,092

67,881

99,719

74,531

16,277

39,981

 Medium follow-up (Months)

46.5

45.5

44.5

44.5

45.5

44.5

43.5

43.5

43.5

41.5

41.5

 Incidence Rate (95% CI)a

10.81 (9.53,12.26)

12.53 (11.38,13.79)

17.04 (15.04,19.32)

20.89 (17.95,24.31)

20.41 (16.96,24.56)

22.69 (19.42,26.51)

21.74 (18.22,25.95)

29.84 (26.35,33.80)

33.17 (28.93,38.02)

36.86 (27.94,48.64)

46.22 (39.47,54.13)

 Hazard Ratio (95% CI)

Reference group

1.07 (0.91,1.26)

1.30* (1.09,1.56)

1.57* (1.28,1.91)

1.42* (1.13,1.78)

1.58* (1.29,1.94)

1.48* (1.19,1.84)

1.94* (1.62,2.33)

2.00* (1.65,2.42)

2.21* (1.63,3.01)

2.57* (2.08,3.17)

All-cause mortality

 Cumulative Cases with Event

138

277

156

126

79

112

115

165

155

45

160

 Cumulative Incidence Rate

2.4%

3.1%

4.1%

5.8%

5.4%

5.9%

7.4%

7.1%

8.8%

11.1%

15.7%

 Person-years

273,362

407,234

176,630

99,035

68,040

86,781

70,042

103,939

78,012

17,049

42,556

 Medium follow-up (Months)

46.5

45.5

45.5

45.5

45.5

44.5

44.5

44.5

44.5

42.5

42.5

 Incidence Rate (95% CI)a

6.06 (5.13,7.16)

8.16

(7.26,9.18)

10.60 (9.06,12.40)

15.27 (12.82,18.18)

13.93 (11.18,17.37)

15.49 (12.87,18.64)

19.70 (16.41,23.65)

19.05 (16.35,22.19)

23.84 (20.37,27.91)

31.67 (23.65,42.42)

45.12 (38.64,52.68)

 Hazard Ratio (95% CI)

Reference group

1.23* (1.00,1.51)

1.41* (1.12,1.77)

1.93* (1.51,2.46)

1.53* (1.16,2.02)

1.79* (1.39,2.31)

2.29* (1.78,2.94)

2.08* (1.65,2.62)

2.41* (1.90,3.05)

3.26* (2.32,4.59)

4.36* (3.43,5.53)

Composite of CVD and mortality

 Cumulative Cases with Event

361

648

359

264

165

239

217

353

315

77

265

 Cumulative Incidence Rate

6.2%

7.4%

9.3%

12.1%

11.2%

12.5%

13.9%

15.3%

17.8%

19.0%

26.0%

 Person-years

268,568

399,457

172,506

95,953

65,849

84,092

67,881

99,719

74,531

16,277

39,981

 Medium follow-up (Months)

46.5

45.5

44.5

44.5

45.5

44.5

43.5

43.5

43.5

41.5

41.5

 Incidence Rate (95% CI)a

16.13 (14.55,17.88)

19.47 (18.02,21.02)

24.97 (22.52,27.69)

33.02 (29.26,37.25)

30.07 (25.81,35.03)

34.11 (30.04,38.72)

38.36 (33.58,43.82)

42.48 (38.27,47.15)

50.72 (45.41,56.64)

56.77 (45.40,70.97)

79.54 (70.52,89.72)

 Hazard Ratio (95% CI)

Reference group

1.14 (1.00,1.29)

1.32* (1.14,1.53)

1.70* (1.45,1.99)

1.37* (1.14,1.65)

1.59* (1.34,1.87)

1.85* (1.56,2.19)

1.88* (1.62,2.18)

2.16* (1.85,2.52)

2.64* (2.06,3.39)

3.41* (2.89,4.03)

  1. Hazard ratios were adjusted for age, gender, smoking status, drinking habit, body mass index, waist-to-hip ratio, glycated hemoglobin A1c, systolic and diastolic blood pressure, low-density lipoprotein-cholesterol, total cholesterol to high-density lipoprotein cholesterol ratio, triglyceride, estimated Glomerular Filtration Rate, self-reported duration of diabetes mellitus, family history of diabetes mellitus, diagnosed hypertension, the usage of anti-hypertensive drugs, oral anti-diabetic drugs, insulin and lipid-lowering agents at baseline
  2. CVD Cardiovascular Diseases, UACR Albumin/Creatinine Ratio
  3. *Significant difference (P < 0.05) by multivariable Cox proportional hazards regression
  4. aIncidence rate (cases/1000 person-years) with 95%CI based on Poisson distribution